Levels of tumor markers in pleural effusions may help to establish the diagnosis of pleural
malignancy, but the precise diagnostic value of each marker remains unclear. The aim of …

INTRODUCTION: Smoking can cause a variety of pulmonary interstitial diseases. Pulmonary
fibrosis has traditionally been considered a non-smoking-related disease. Recently …

Progressive multifocal leukoencephalopathy (PML) is a demyelinating infection caused by
the JC virus. It is an emerging disease in transplant recipients; however, it remains poorly …

Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin. The drug has been tested previously in the phase 3 NAVIGATOR …

Background Silicosis is a progressive, fibrotic, occupational lung disease resulting from
inhalation of respirable crystalline silica. This disease is preventable through appropriate …

Obstructive sleep apnea (OSA) shares many cardiovascular risk factors with metabolic
syndrome, including obesity, hypertension, insulin resistance, and pro-inflammatory state …

Background Tranexamic acid (TA) is an antifibrinolytic drug currently used systemically to
control bleeding. To date, there have been no prospective studies of the effectiveness of …

BACKGROUND: Rehabilitation is a central treatment modality for patients with chronic
cardiopulmonary disease. Physical exertion for patients with pulmonary arterial …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease
characterized by a progressive decline in lung function. Fibrotic diseases, such as IPF, are …

Background Management of benign tracheal stenosis (BTS) varies with the type and extent
of the disease and influenced by the patient's age and general health status, hence we …